The clinical effectiveness of the current generation of heart failure biomarkers is limited by the need to repeatedly measure multiple individual markers in order to generate a full risk profile of a HF patient. The classical HF protein markers either have diagnostic or prognostic properties, while measuring multiple protein biomarkers is time-consuming and expensive since costs are additive for each marker.
Despite advances in treatment of HF, patients have a poor prognosis and up to 50% die within 5 years. HF is the single most frequent cause of hospitalisation in elderly and its societal costs are enormous. There is increasing need for preventive measures and for novel biomarkers to improve clinical management of HF. The introduction of miRNAs as biomarkers for cardiovascular disease and the dramatic progress of novel multiplexing technologies open up the opportunity to develop new diagnostic tests that provide more and more specific information about the cardiovascular condition of an individual patient.
ACS Biomarker is picking up the challenge to develop the first combined miRNA and protein based multi-marker test that simultaneously provides diagnostic and prognostic information. A quick and simplified diagnostic procedure that leads to a better understanding of a patient's risk profile resulting in better treatment decisions and improved outcomes